Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More
GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More
SUN PHARMA | GSK PHARMA | SUN PHARMA/ GSK PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 74.2 | 51.3 | 144.7% | View Chart |
P/BV | x | 3.2 | 11.6 | 27.4% | View Chart |
Dividend Yield | % | 0.7 | 1.4 | 49.1% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
SUN PHARMA Mar-20 |
GSK PHARMA Mar-19 |
SUN PHARMA/ GSK PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 484 | 3,595 | 13.5% | |
Low | Rs | 315 | 1,253 | 25.2% | |
Sales per share (Unadj.) | Rs | 136.9 | 184.7 | 74.1% | |
Earnings per share (Unadj.) | Rs | 17.5 | 26.3 | 66.4% | |
Cash flow per share (Unadj.) | Rs | 26.0 | 29.2 | 89.2% | |
Dividends per share (Unadj.) | Rs | 4.00 | 20.00 | 20.0% | |
Dividend yield (eoy) | % | 1.0 | 0.8 | 121.3% | |
Book value per share (Unadj.) | Rs | 188.7 | 126.3 | 149.4% | |
Shares outstanding (eoy) | m | 2,399.26 | 169.40 | 1,416.3% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 2.9 | 13.1 | 22.2% | |
Avg P/E ratio | x | 22.9 | 92.2 | 24.8% | |
P/CF ratio (eoy) | x | 15.4 | 83.1 | 18.5% | |
Price / Book Value ratio | x | 2.1 | 19.2 | 11.0% | |
Dividend payout | % | 22.9 | 76.1 | 30.1% | |
Avg Mkt Cap | Rs m | 958,864 | 410,626 | 233.5% | |
No. of employees | `000 | 17.8 | 5.0 | 358.0% | |
Total wages/salary | Rs m | 63,624 | 5,372 | 1,184.4% | |
Avg. sales/employee | Rs Th | 18,490.6 | 6,306.7 | 293.2% | |
Avg. wages/employee | Rs Th | 3,582.6 | 1,083.1 | 330.8% | |
Avg. net profit/employee | Rs Th | 2,357.6 | 898.0 | 262.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 328,375 | 31,281 | 1,049.8% | |
Other income | Rs m | 6,360 | 1,023 | 621.6% | |
Total revenues | Rs m | 334,735 | 32,304 | 1,036.2% | |
Gross profit | Rs m | 69,898 | 6,009 | 1,163.2% | |
Depreciation | Rs m | 20,528 | 486 | 4,223.8% | |
Interest | Rs m | 3,027 | 6 | 50,455.0% | |
Profit before tax | Rs m | 52,702 | 6,540 | 805.8% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | -2,606 | 287 | -908.2% | |
Tax | Rs m | 8,228 | 2,373 | 346.7% | |
Profit after tax | Rs m | 41,868 | 4,454 | 940.0% | |
Gross profit margin | % | 21.3 | 19.2 | 110.8% | |
Effective tax rate | % | 15.6 | 36.3 | 43.0% | |
Net profit margin | % | 12.8 | 14.2 | 89.5% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 316,542 | 20,061 | 1,577.9% | |
Current liabilities | Rs m | 157,064 | 14,543 | 1,080.0% | |
Net working cap to sales | % | 48.6 | 17.6 | 275.3% | |
Current ratio | x | 2.0 | 1.4 | 146.1% | |
Inventory Days | Days | 88 | 57 | 154.2% | |
Debtors Days | Days | 105 | 14 | 744.8% | |
Net fixed assets | Rs m | 243,102 | 14,343 | 1,694.9% | |
Share capital | Rs m | 2,399 | 1,694 | 141.6% | |
"Free" reserves | Rs m | 450,245 | 19,704 | 2,285.0% | |
Net worth | Rs m | 452,645 | 21,398 | 2,115.3% | |
Long term debt | Rs m | 20,289 | 2 | 1,014,460.0% | |
Total assets | Rs m | 682,525 | 39,113 | 1,745.0% | |
Interest coverage | x | 18.4 | 1,091.0 | 1.7% | |
Debt to equity ratio | x | 0 | 0 | 47,957.5% | |
Sales to assets ratio | x | 0.5 | 0.8 | 60.2% | |
Return on assets | % | 6.6 | 11.4 | 57.7% | |
Return on equity | % | 9.2 | 20.8 | 44.4% | |
Return on capital | % | 11.2 | 31.9 | 35.2% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 74,219 | 534 | 13,898.6% | |
Fx outflow | Rs m | 27,964 | 7,091 | 394.4% | |
Net fx | Rs m | 46,255 | -6,557 | -705.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 65,548 | 3,994 | 1,641.2% | |
From Investments | Rs m | -25,888 | -1,433 | 1,806.1% | |
From Financial Activity | Rs m | -57,151 | -3,584 | 1,594.8% | |
Net Cashflow | Rs m | -13,857 | -1,023 | 1,354.3% |
Indian Promoters | % | 63.7 | 0.0 | - | |
Foreign collaborators | % | 0.0 | 50.7 | - | |
Indian inst/Mut Fund | % | 5.1 | 10.2 | 50.3% | |
FIIs | % | 23.0 | 23.8 | 96.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 8.3 | 15.4 | 53.9% | |
Shareholders | 133,026 | 102,036 | 130.4% | ||
Pledged promoter(s) holding | % | 0.5 | 0.0 | - |
Compare SUN PHARMA With: DR. DATSONS LABS DISHMAN PHARMA TTK HEALTHCARE JUBILANT LIFE SCIENCES DIVIS LABORATORIES
Compare SUN PHARMA With: ACTAVIS (US) MYLAN (US) ADCOCK INGRAM (S. Africa) TEVA PHARMA (Israel)
The market see-sawed during the week with both the bulls and bears swinging it out. But in the end, it was the bears who won. The Nifty ended the day, the week, and the month at 14,529.15.
For the quarter ended December 2020, GSK PHARMA has posted a net profit of Rs 2 bn (up 124.4% YoY). Sales on the other hand came in at Rs 9 bn (up 10.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
For the quarter ended December 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 87.4% YoY). Sales on the other hand came in at Rs 88 bn (up 8.4% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
Here's an analysis of the annual report of SUN PHARMA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.
For the quarter ended September 2020, SUN PHARMA has posted a net profit of Rs 19 bn (up 66.9% YoY). Sales on the other hand came in at Rs 86 bn (up 5.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.
For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll cover your queries on intraday trading and also share my view on how to decide stop losses and target prices.
A look at what India's top equity mutual funds bought and sold in January 2021.
Do you enjoy reading Tesla and Bitcoin stories? Here's a not so famous small-cap stock to profit from the rise of EVs.
More